Vanguard Group Inc. Buys 486,607 Shares of Guardant Health, Inc. (NASDAQ:GH)

Vanguard Group Inc. raised its stake in Guardant Health, Inc. (NASDAQ:GH) by 6.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,627,500 shares of the company’s stock after buying an additional 486,607 shares during the period. Vanguard Group Inc. owned about 8.52% of Guardant Health worth $1,071,448,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Prudential Financial Inc. grew its position in shares of Guardant Health by 0.3% in the 1st quarter. Prudential Financial Inc. now owns 40,099 shares of the company’s stock valued at $6,121,000 after buying an additional 128 shares during the last quarter. Quilter Plc boosted its position in shares of Guardant Health by 6.4% during the 2nd quarter. Quilter Plc now owns 2,334 shares of the company’s stock valued at $290,000 after purchasing an additional 141 shares in the last quarter. Heritage Wealth Advisors boosted its position in shares of Guardant Health by 37.1% during the 2nd quarter. Heritage Wealth Advisors now owns 591 shares of the company’s stock valued at $76,000 after purchasing an additional 160 shares in the last quarter. Private Advisor Group LLC boosted its position in shares of Guardant Health by 9.3% during the 2nd quarter. Private Advisor Group LLC now owns 1,926 shares of the company’s stock valued at $239,000 after purchasing an additional 164 shares in the last quarter. Finally, Arden Trust Co boosted its position in shares of Guardant Health by 2.4% during the 2nd quarter. Arden Trust Co now owns 8,326 shares of the company’s stock valued at $1,034,000 after purchasing an additional 196 shares in the last quarter. Hedge funds and other institutional investors own 87.58% of the company’s stock.

Several brokerages recently commented on GH. TheStreet upgraded Guardant Health from a “d” rating to a “c-” rating in a research report on Monday, October 4th. Wells Fargo & Company increased their price target on Guardant Health from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, June 21st. Zacks Investment Research lowered Guardant Health from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Canaccord Genuity cut their price target on Guardant Health from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Monday, August 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $164.00.

In other news, Director Stanley J. Meresman sold 4,934 shares of the firm’s stock in a transaction on Monday, October 11th. The stock was sold at an average price of $103.59, for a total value of $511,113.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 14,802 shares of company stock valued at $1,715,453 over the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Shares of NASDAQ GH opened at $102.01 on Thursday. The stock has a fifty day simple moving average of $117.43 and a two-hundred day simple moving average of $125.90. Guardant Health, Inc. has a 1-year low of $96.66 and a 1-year high of $181.07. The firm has a market cap of $10.33 billion, a price-to-earnings ratio of -27.06 and a beta of 0.51. The company has a current ratio of 19.57, a quick ratio of 19.30 and a debt-to-equity ratio of 1.44.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, August 5th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.09). Guardant Health had a negative net margin of 116.99% and a negative return on equity of 37.35%. The firm had revenue of $92.10 million for the quarter, compared to the consensus estimate of $84.63 million. Analysts forecast that Guardant Health, Inc. will post -3.98 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.

Read More: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.